SEXUAL HEALTH & VITALITY RESEARCH
Bremelanotide—acts on the brain to trigger sexual desire, rather than on blood flow.
PT-141 (bremelanotide) acts on the brain to trigger sexual arousal and desire—a different route from drugs like Viagra, which only affect blood flow. It is FDA-approved in its clinical formulation for hypoactive sexual desire disorder (persistently low sexual desire that causes distress).
Included because it is FDA-approved in its clinical formulation, works through a well-characterized central melanocortin mechanism, and has measurable outcomes in sexual-desire research. It anchors the established end of the sexual-health research spectrum.
Binds MC4R receptors in the central nervous system.
Activates the brain's sexual-arousal pathway, increasing desire and sensitivity.
Acts on the brain rather than on blood flow, and is studied in both men and women.
WHAT THE RESEARCH MEASURED
Findings describe study outcomes, not expected personal results.
PT-141 (bremelanotide) is FDA-approved in its clinical formulation. Material offered here is sold and offered strictly for laboratory and research use.
